Sixteen were excluded from further analysis due to the following technical reasons: six patients did not consume rivaroxaban after breakfast since they had to fast before a certain procedure, five patients were released from the hospital before we managed to withdraw a second sample, three patients undergone procedures during the time the second sample was about to be taken, one patient was diagnosed with cancer during his current hospitalization and one blood sample volume was insufficient to perform the anti-FXa test. This evidence concerns the gene F10 and cancer.